BioCryst director granted 1,159 shares at $9.70

Biocryst director and Board Chair Vincent Milano received stock in place of part of his quarterly cash retainer, modestly increasing his direct holdings.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Vincent Milano received an award of 1,159 shares of Common Stock on August 31, 2026. These shares were issued in lieu of 50% of his quarterly Board Chair cash retainer of $22,500, equating to a value of $9.70 per share. Following this grant, Milano directly holds 109,642 shares of Biocryst common stock. No transactions were reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 1,159 shares

Grant/Award 1 txn

Insider MILANO VINCENT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	1,159	$9.70	$11K

Holdings After Transaction: Common Stock — 109,642 shares (Direct)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.

Key Figures

Shares awarded: 1,159 shares Per-share value for award: $9.70 per share Quarterly Board Chair retainer: $22,500 +1 more

4 metrics

Shares awarded 1,159 shares Common Stock granted to director Vincent Milano on August 31, 2026

Per-share value for award $9.70 per share Value used for the 1,159-share stock award tied to Board Chair retainer

Quarterly Board Chair retainer $22,500 Cash retainer for Board Chair; 50% paid in stock via this award

Shares owned after transaction 109,642 shares Total direct Biocryst holdings of Vincent Milano after the grant

Key Terms

Board Chair retainer, Rule 10b5-1, grant, award, or other acquisition

3 terms

Board Chair retainer financial

"in lieu of 50% of the quarterly cash Board Chair retainer of $22,500"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

grant, award, or other acquisition financial

"classified as a grant, award, or other acquisition of Common Stock"

FAQ

What insider transaction did BCRX director Vincent Milano report on August 31, 2026?

He reported an award of 1,159 shares of Biocryst Common Stock on August 31, 2026, classified as a grant or other acquisition rather than an open-market purchase.

Why did Vincent Milano receive 1,159 BCRX shares instead of cash?

The 1,159 shares were issued to Vincent Milano in lieu of 50% of his quarterly $22,500 Board Chair cash retainer, effectively paying part of his board compensation in stock.

What was the implied value per BCRX share in Milano’s August 31, 2026 award?

The filing reports a value of $9.70 per share for the 1,159-share award issued to Vincent Milano on August 31, 2026, tied to his Board Chair retainer compensation.

How many BCRX shares does Vincent Milano hold after this Form 4 transaction?

After the August 31, 2026 stock award, Vincent Milano directly owns 109,642 shares of Biocryst common stock, as reported in the Form 4.

Was Vincent Milano’s August 31, 2026 BCRX stock award under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan for this transaction; it is reported as a compensation-related grant rather than plan-based trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:10 PM Accepted by SEC EDGAR 09/02/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILANO VINCENT

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A		1,159(1)	A	$9.7	109,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.

	/s/ Alane P. Barnes, by power of attorney	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)